FILING ANALYSIS · MONDAY, NOVEMBER 9
Larimar Therapeutics, Inc. LRMR — 8-K: Results of Operations and Financial Condition
neutral
Larimar Therapeutics has completed its rolling Biologics License Application submission to the FDA for accelerated approval of nomlabofusp, a potential disease-modifying therapy for Friedreich's ataxia, and has approximately $128.7 million in cash and cash equivalents as of September 30, 2026. The submission is a significant milestone, but the impact on the stock price will depend on the FDA's rev
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →